ArticlePloS one2026
Spatial compartmentalization of melanoma cell states reveals CAF-associated tumor cells with enhanced proliferative capacity.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer-associated fibroblasts (CAFs) are key components of the melanoma tumor microenvironment and have been implicated in immune evasion and therapy resistance. However, the spatial relationships between CAFs, extracellular matrix (ECM) remodeling, and immune exclusion remain incompletely characterized.
methodsWe integrated single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics from primary melanoma samples (892 regions of interest) to investigate the landscape of CAF-immune interactions. CAF scores were calculated based on five fibroblast-associated genes. Differential expression analysis, Spearman correlation, and cell state subclustering were performed to characterize the spatial organization of the tumor microenvironment. Findings were examined using TCGA bulk RNA-seq data and drug sensitivity was assessed using the GDSC database.
resultsCAF-high regions exhibited significantly lower immune scores compared to CAF-low regions (ρ = -0.442, p < 0.001), with enrichment of ECM-related genes (COL1A1, COL1A2, DCN, FBLN1) and downregulation of immune genes (PTPRC, CD4, CD8A). Spatial co-expression of FN1 and its integrin receptor subunit ITGB1 was observed (ρ = 0.100, p = 0.003), supporting a potential role for ECM-receptor signaling in immune exclusion. Six distinct melanoma cell states were identified, with CAF-associated tumor states (State 4) exhibiting significantly higher proliferative capacity than immune-associated states (State 5) (p = 0.007). The CAF signature correlated with cisplatin sensitivity (ρ = -0.627, p < 0.001) and trametinib resistance (ρ = 0.354, p = 0.009).
conclusionsThis study provides a spatial atlas of CAF-immune interactions in melanoma. CAF abundance is negatively correlated with immune infiltration at the spatial level, with ECM remodeling and FN1-ITGB1 signaling potentially mediating this immune exclusion. The CAF signature showed correlations with drug sensitivity in cell line models, warranting further investigation in CAF-containing systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.